MYC and neoplasm: qPCR evaluation of cabozantinib effects on genes associated with tumor progression revealed decreased levels of MYC (−38% P=0.092), increased levels of the human homolog of endoglin (+185%, P=0.0058) and no alteration in the levels of cyclin D. Evaluating the alteration of genes associated with apoptosis showed a trend to decreased survivin (~-39%, P=0.025), but no alteration in levels of BCL2 and BIM (Figure S3).